Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study

Figure 5

Flow chart of study progress, including recruitment and monitoring of study participants: study participants consisted of nontumoral controls () and patients with first time breast cancer diagnoses (BCD) (). Patients with BCD were further divided into two group based on treatment modality (adjuvant chemotherapy, vs. neoadjuvant chemotherapy, ). All patients in the study received taxane therapy as part of their chemotherapy regimen. Stromal and plasma levels of Gal-3 were measured at the time of recruitment and throughout the treatment period. Following end of treatment, patients were monitored for a total of 84 months for disease-free survival (DFS).